Hap Trading, LLC Revance Therapeutics, Inc. Call Options Transaction History

Hap Trading, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 11, 2023	SELL	$24.7 - $37.61 $83,980 - $127,874	-3,400 Reduced 1.34%	250,000 $6.33 Million
Q1 2023 May 12, 2023	BUY	$18.36 - $35.27 $4.65 Million - $8.94 Million	253,400 New	253,400 $2.72 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $288,033 - $572,247	20,100 Added 176.32%	31,500 $168,000
Q2 2022 Aug 12, 2022	BUY	$11.52 - $20.4 $131,328 - $232,559	11,400 New	11,400 $10,000
Q1 2022 May 12, 2022	SELL	$12.36 - $20.31 $179,220 - $294,495	-14,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $46,102 - $103,119	3,700 Added 34.26%	14,500 $9,000
Q1 2020 May 08, 2020	SELL	$12.46 - $27.81 $184,408 - $411,588	-14,800 Reduced 57.81%	10,800 $7,000
Q4 2019 Feb 11, 2020	BUY	$11.66 - $20.15 $298,496 - $515,839	25,600 New	25,600 $7,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.